BVT Call 125 ABT 20.09.2024/ DE000VM7N0K2 /
09/09/2024 19:42:56 | Chg.+0.001 | Bid20:52:52 | Ask20:52:52 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.003EUR | +50.00% | - Bid Size: - |
- Ask Size: - |
Abbott Laboratories | 125.00 USD | 20/09/2024 | Call |
GlobeNewswire
06/08
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
GlobeNewswire
06/06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
09/05
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
25/03
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
15/03
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
14/11/2023
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
19/10/2023
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
10/10/2023
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
02/10/2023
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors